
Boston Scientific (BSX): Growth Reset Before the Next Upcycle
Boston Scientific is a high-quality medtech franchise with strong cash generation and a broad pipeline, but near-term growth is being pressured by EP, WATCHMAN, and China-related weakness. The stock looks attractive for patient investors, with multiple recovery catalysts still ahead.






